Literature DB >> 34889416

Indications for transfusion in the management of sickle cell disease.

Hyojeong Han1,2, Lisa Hensch3,4, Venée N Tubman1,2.   

Abstract

The transfusion of red blood cells (RBCs) is a crucial treatment for sickle cell disease (SCD). While often beneficial, the frequent use of transfusions is associated with numerous complications. Transfusions should be offered with specific guidelines in mind. Here we present updates to the indications for transfusion of RBCs in SCD. We review recent publications and include expert perspectives from hematology and transfusion medicine. For some clinical indications, such as ischemic stroke, the role of transfusion has been well studied and can be applied almost universally. For many other clinical scenarios, the use of transfusion therapy has less conclusive data and therefore must be tailored to individual needs. We highlight the roles of RBC transfusions in preventing or mitigating neurological disease, in reducing perioperative complications, in managing acute chest syndrome, and in optimizing pregnancy outcomes in SCD. We further highlight various transfusion techniques and when each might be considered. Potential complications of transfusion are also briefly discussed.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2021        PMID: 34889416      PMCID: PMC8791131          DOI: 10.1182/hematology.2021000307

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  54 in total

1.  Guidelines on red cell transfusion in sickle cell disease Part II: indications for transfusion.

Authors:  Bernard A Davis; Shubha Allard; Amrana Qureshi; John B Porter; Shivan Pancham; Nay Win; Gavin Cho; Kate Ryan
Journal:  Br J Haematol       Date:  2016-11-18       Impact factor: 6.998

Review 2.  Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature.

Authors:  Athira Unnikrishnan; J Peter R Pelletier; Shahla Bari; Marc Zumberg; Abbas Shahmohamadi; Bruce D Spiess; Mary Jane Michael; Neil Harris; Danielle Harrell; Molly W Mandernach
Journal:  Transfusion       Date:  2019-02-15       Impact factor: 3.157

3.  Acute Chest Syndrome After Splenectomy in Children With Sickle Cell Disease.

Authors:  Yousef El-Gohary; Andrew Fleming; Hui Zhang; Jeremie H Estepp; Jane S Hankins; Winfred Wang; Andrew M Davidoff; Andrew J Murphy
Journal:  J Surg Res       Date:  2019-05-23       Impact factor: 2.192

Review 4.  Mechanisms of sickle cell alloimmunization.

Authors:  K Yazdanbakhsh
Journal:  Transfus Clin Biol       Date:  2015-06-06       Impact factor: 1.406

5.  Cerebrovascular accidents in sickle cell disease: rates and risk factors.

Authors:  K Ohene-Frempong; S J Weiner; L A Sleeper; S T Miller; S Embury; J W Moohr; D L Wethers; C H Pegelow; F M Gill
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

Review 6.  Recommendations for the use of red blood cell exchange in sickle cell disease.

Authors:  Romain Fort
Journal:  Transfus Apher Sci       Date:  2019-03-13       Impact factor: 1.764

7.  Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group.

Authors:  E P Vichinsky; L D Neumayr; A N Earles; R Williams; E T Lennette; D Dean; B Nickerson; E Orringer; V McKie; R Bellevue; C Daeschner; E A Manci
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

Review 8.  Transfusion Therapy in Children With Sickle Cell Disease.

Authors:  Adlette Inati; Anthony G Mansour; Toni Sabbouh; Ghid Amhez; Ahmad Hachem; Hussein A Abbas
Journal:  J Pediatr Hematol Oncol       Date:  2017-03       Impact factor: 1.289

9.  Association of Antibiotic Choice With Hospital Length of Stay and Risk Factors for Readmission in Patients With Sickle Cell Disease and Acute Chest Syndrome: An Observational Cohort Study.

Authors:  Oluwakemi Badaki-Makun; James F Casella; Sean Tackett; Xueting Tao; James M Chamberlain
Journal:  Ann Emerg Med       Date:  2020-09       Impact factor: 5.721

10.  Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.

Authors:  Najibah A Galadanci; Shehu U Abdullahi; Shehi Ali Abubakar; Binta Wudil Jibir; Hauwa Aminu; Aliyu Tijjani; Muhammad S Abba; Musa A Tabari; Aisha Galadanci; Awwal Musa Borodo; Raymond Belonwu; Auwal S Salihu; Mark Rodeghier; Djamila L Ghafuri; Brittany V Covert C Greene; Kathleen Neville; Adetola A Kassim; Fenella J Kirkham; Lori C Jordan; Muktar H Aliyu; Michael R DeBaun
Journal:  Am J Hematol       Date:  2020-07-10       Impact factor: 10.047

View more
  1 in total

1.  Role of Serum Ferritin in Predicting Outcomes of COVID-19 Infection Among Sickle Cell Disease Patients: A Systematic Review and Meta-Analysis.

Authors:  Jun Xin Lee; Wei Keong Chieng; Muhammad Irfan Abdul Jalal; Chai Eng Tan; Sie Chong Doris Lau
Journal:  Front Med (Lausanne)       Date:  2022-05-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.